Early results promise a one-off treatment, but gene-editing and gene therapies will have to show durable protection and be affordable to the many patients with sickle cell disease in the world.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Change history
27 December 2021
A Correction to this paper has been published: https://doi.org/10.1038/s41587-021-01193-y
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. Sickle cell gene therapies approach watershed. Nat Biotechnol 39, 1320–1323 (2021). https://doi.org/10.1038/s41587-021-01121-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-021-01121-0